Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study
Status:
Withdrawn
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
Comorbid substance abuse leads to many deleterious effects such as medical comorbidities and
nonadherence, which is one of the most problematic issues. People with schizophrenia and
substance use disorders (SUDs) are at an increased risk nonadherence compared to those who do
not use alcohol and illicit drugs. The investigators propose that this new marketed
injectable antipsychotic with many benefits over other available long acting injectable
agents would be beneficial in the dually diagnosed population and may represent a specific
schizophrenia subpopulation where long acting agents may be considered an important
therapeutic option.
Phase:
N/A
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore